MGI(SH:688114)2022-10-19 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥928,958,162.52, representing a year-over-year increase of 4.63%[4]. - The net profit attributable to shareholders for Q3 2022 was ¥1,678,255,089.16, with a year-to-date increase of 339.85% to ¥4,717,830,352.49[4][9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥44,033,703.73, showing a year-to-date decrease of 24.96%[4]. - The basic earnings per share for Q3 2022 was ¥4.39, with a year-to-date increase of 334.32% to ¥4,582.08[5][9]. - The total profit for the period is approximately CNY 2.62 billion, compared to CNY 541.38 million in the previous period, indicating a significant increase[33]. - The net profit attributable to shareholders of the parent company is approximately CNY 2.02 billion, up from CNY 459.69 million year-over-year[35]. - The basic earnings per share (EPS) is CNY 5.39, compared to CNY 1.24 in the previous period, reflecting a substantial growth in profitability[35]. - The company reported a total comprehensive income for the period of approximately CNY 2.12 billion, compared to CNY 444.12 million in the previous period, indicating robust overall performance[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥11,736,266,013.61, reflecting a 97.47% increase compared to the same period last year[5][10]. - The equity attributable to shareholders at the end of Q3 2022 was ¥9,411,389,087.31, an increase of 134.87% year-over-year[5][10]. - The total liabilities increased to CNY 2.28 billion from CNY 1.87 billion, representing a growth of 21.9%[30]. - Current assets rose to CNY 9.83 billion, compared to CNY 4.27 billion in the previous year, marking an increase of 130.5%[23]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥2,072,381,921.40, reflecting a 250.19% increase[5][9]. - Cash inflows from operating activities totaled approximately CNY 5.66 billion, compared to CNY 3.51 billion in the previous year, showing a strong operational performance[36]. - The net cash flow from operating activities is approximately CNY 2.07 billion, a significant increase from CNY 591.79 million in the previous period[37]. - The company reported a net increase in cash and cash equivalents of approximately CNY 5.23 billion, compared to a decrease of CNY 529.98 million in the previous year[39]. - The company has successfully managed its financial activities, with cash inflows from financing activities amounting to approximately CNY 3.35 billion, compared to CNY 30 million in the previous year[37]. Research and Development - Research and development expenses for Q3 2022 totaled ¥193,767,510.81, accounting for 20.86% of operating revenue, which is an increase of 1.37 percentage points[5]. - Research and development expenses for the third quarter of 2022 were CNY 525.32 million, up from CNY 456.54 million in the same quarter of 2021, indicating a growth of 15.0%[32]. - The company plans to continue expanding its market presence and investing in R&D to enhance product offerings and technological advancements[5]. - The company has ongoing investments in new technologies and products, with a focus on expanding its market presence and enhancing R&D capabilities[31]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,587[11]. - Shenzhen BGI Intelligent Manufacturing Co., Ltd. holds 153,001,440 shares, accounting for 37.04% of the total shares[11]. - The top ten shareholders include CPE Investment (Hong Kong) 2018 Limited, holding 26,378,788 shares, which is 6.39% of the total shares[11]. - The company has not disclosed any related party transactions or concerted actions among the top ten shareholders beyond those mentioned[14]. Impairment Losses - The company recognized credit impairment losses of RMB 22,445,113.23 for accounts receivable and RMB 536,470.58 for other receivables during the reporting period[17]. - The total asset impairment losses for the first nine months of 2022 amounted to RMB 59,057,585.15, which will reduce the total profit for the consolidated financial statements[17]. - The company reported a credit impairment loss of RMB 36,076,001.34 for inventory during the reporting period[17]. Strategic Plans - The company plans to jointly bid for land in Yantian District with Shenzhen BGI Gene Technology Co., Ltd. and other related parties[15]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[40]. - The company received a net compensation of $325 million from Illumina, significantly impacting net profit and cash flow[9][10]. - The company received a net compensation of USD 325 million from Illumina as part of a settlement agreement[16]. - The company has canceled the qualifications of 16 incentive objects due to personal reasons, resulting in the cancellation of 228,100 stock options[16].